The CHOLINE-2 Study is a Phase 3 clinical trial comparing the effectiveness of donepezil versus non-drug approaches in the treatment of newly diagnosed Alzheimer's disease. This comparative effectiveness trial addresses an important clinical question: whether pharmacological treatment with acetylcholinesterase inhibitors provides superior benefit compared to non-pharmacological interventions alone in early-stage AD.
| Attribute |
Value |
| NCT ID |
NCT04661280 |
| Phase |
Phase 3 |
| Status |
Recruiting |
| Intervention |
Donepezil vs Non-drug Approach |
| Condition |
Newly Diagnosed Alzheimer's Disease |
| Participants |
240 |
| Sponsor |
Assistance Publique - Hôpitaux de Paris |
| Study Design |
Randomized, open-label, parallel-group |
The cholinergic hypothesis of Alzheimer's disease was first proposed in the 1970s and remains a foundational concept in AD therapeutics. The hypothesis posits that degeneration of cholinergic neurons in the basal forebrain and their projections to the cortex and hippocampus contributes significantly to the cognitive deficits characteristic of AD.
Key Evidence Supporting the Cholinergic Hypothesis:
- Neuropathological findings: Post-mortem studies demonstrate significant loss of cholinergic neurons in the nucleus basalis of Meynert in AD patients
- Neurochemical deficits: Marked reduction in acetylcholine and choline acetyltransferase activity in AD brain tissue
- Correlation with cognition: Cholinergic marker levels correlate with cognitive test scores
- Therapeutic validation: Cholinesterase inhibitors provide modest cognitive benefits, supporting the hypothesis
Donepezil is a reversible acetylcholinesterase inhibitor that works by:
- Enzyme inhibition: Blocks the breakdown of acetylcholine in the synaptic cleft
- Increased acetylcholine: Elevates extracellular acetylcholine levels
- Enhanced cholinergic transmission: Improves signaling through nicotinic and muscarinic receptors
Pharmacological Properties:
- Oral administration (5mg or 10mg daily)
- Long half-life allowing once-daily dosing
- Selective for acetylcholinesterase over butyrylcholinesterase
- Minimal hepatic metabolism with low drug interaction potential
Cognitive Training:
- Structured exercises targeting memory, attention, and executive function
- Computer-based and therapist-guided programs
- Evidence for improvement in specific cognitive domains
Cognitive Stimulation:
- Group-based activities designed to improve social engagement and cognition
- Reality orientation, validation therapy techniques
- Benefits for mood and behavioral symptoms
Physical Activity:
- Regular aerobic exercise improves cerebral blood flow
- May reduce amyloid burden and tau pathology
- Associated with better cognitive outcomes in epidemiological studies
Dietary Interventions:
- Mediterranean diet adherence correlates with reduced AD risk
- Specific nutrients (omega-3 fatty acids, vitamins) may provide neuroprotection
Caregiver Education and Support:
- Training in communication strategies
- Behavioral management techniques
- Stress reduction for caregivers
Environmental Modifications:
- Home safety modifications
- Routine establishment
- Assistive devices for daily activities
¶ Trial Design and Rationale
The CHOLINE-2 trial seeks to answer critical questions about AD treatment:
Primary Objectives:
- Compare cognitive outcomes between donepezil and non-drug approaches
- Assess functional and behavioral outcomes
- Evaluate quality of life measures
Secondary Objectives:
- Cost-effectiveness analysis
- Caregiver burden assessment
- Long-term follow-up outcomes
Inclusion Criteria:
- Newly diagnosed AD (within 12 months of diagnosis)
- MMSE score 20-26 (mild disease)
- Age 65-85 years
- Stable concomitant medications
- Available caregiver/informant
Exclusion Criteria:
- Previous cholinesterase inhibitor use
- Significant psychiatric comorbidity
- Uncontrolled medical conditions
| Arm |
Description |
Duration |
| Donepezil |
5-10mg daily |
52 weeks |
| Non-drug |
Cognitive/lifestyle intervention |
52 weeks |
Multiple randomized controlled trials have demonstrated the benefits of donepezil:
Cognitive Outcomes:
- 2-3 point improvement on MMSE versus placebo
- Benefits observed within 3-6 weeks of treatment
- Continued benefit over 12-24 months of treatment
Functional Outcomes:
- Slowed decline in activities of daily living
- Delayed time to nursing home placement in some studies
- Reduced caregiver burden
Behavioral Outcomes:
- Reduction in apathy and agitation
- Improvement in neuropsychiatric symptoms
Despite widespread use, cholinesterase inhibitors have limitations:
- Modest effect size: Clinical significance variable
- Symptomatic only: No disease-modifying effect
- Response variability: Not all patients benefit
- Side effects: Gastrointestinal symptoms, insomnia
Systematic reviews support the use of cognitive interventions:
Cognitive Training:
- Moderate evidence for improvement in specific domains
- Transfer to daily activities in some studies
Cognitive Stimulation:
- Small but significant benefits for cognition
- Additional benefits for mood and quality of life
Exercise:
- Strong evidence for cognitive benefit
- Dose-response relationship with exercise intensity
Multicomponent Interventions:
- Combined diet, exercise, cognitive training show promise
- FINGER trial demonstrated feasibility and benefit
- Established efficacy from multiple RCTs
- Widely available and approved
- Well-characterized safety profile
- Objective mechanism of action
- No pharmacological side effects
- Addresses multiple domains
- Can be combined with medications
- Patient empowerment and engagement
- Lower cost in some healthcare systems
The CHOLINE-2 trial will provide valuable data for:
- Treatment guidelines: Evidence-based recommendations
- Shared decision-making: Patient preferences
- Resource allocation: Healthcare planning
- Combination approaches: Future trial design
| Measure |
Description |
| MMSE |
Mini-Mental State Examination |
| ADCS-ADL |
Alzheimer's Disease Cooperative Study Activities of Daily Living |
| NPI |
Neuropsychiatric Inventory |
- Quality of life (QoL-AD)
- Caregiver burden (Zarit Burden Interview)
- Cost-effectiveness measures
- Biomarker substudies
¶ Safety and Tolerability
| Adverse Event |
Frequency |
| Nausea |
10-20% |
| Diarrhea |
5-15% |
| Insomnia |
5-10% |
| Muscle cramps |
3-5% |
- Minimal physical risks
- Psychological considerations
- Accessibility of interventions
- Donepezil superiority: Supports early pharmacological intervention
- Non-drug superiority: Emphasizes lifestyle interventions
- Comparable outcomes: Suggests combination approaches
- Subgroup effects: Personalized treatment recommendations
As disease-modifying therapies become available (anti-amyloid, anti-tau antibodies), the role of symptomatic treatments will evolve. Combination approaches may become standard of care.